[go: up one dir, main page]

NO20055588L - Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2 - Google Patents

Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2

Info

Publication number
NO20055588L
NO20055588L NO20055588A NO20055588A NO20055588L NO 20055588 L NO20055588 L NO 20055588L NO 20055588 A NO20055588 A NO 20055588A NO 20055588 A NO20055588 A NO 20055588A NO 20055588 L NO20055588 L NO 20055588L
Authority
NO
Norway
Prior art keywords
crth2
diseases
treatment
pyrimidine derivatives
allergic
Prior art date
Application number
NO20055588A
Other languages
English (en)
Other versions
NO20055588D0 (no
Inventor
Takashi Yoshino
Takuya Shintani
Klaus Urbahns
Kevin Bacon
Hiromi Sugimoto
Tai-Wei Ly
Yuji Koriyama
Hiroki Sato
Kazuho Tanaka
Yoshihisa Manabe
Masanori Seki
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of NO20055588D0 publication Critical patent/NO20055588D0/no
Publication of NO20055588L publication Critical patent/NO20055588L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives et pyrimidin derivat med formel (I) og salter derav som er brukbare som aktive bestanddeler i farmasøytiske preparater. Pyrimidin derivatene har utmerket CRTH2 (G-protein- koblet, kjemoattraktant reseptor, uttrykt på Th2 celler) antagonistisk aktivitet og kan benyttes for profylakse og terapi av sykdonmier assosiert med CRTH2 aktivitet, særlig for behandling av allergiske sykdommer som astma, allergisk rinitt, atopisk dermatitt og allergisk konjunktivitt; eosinofil-relaterte sykdommer som Churg- Sfrauss syndrom og sinusitt; basofil-relaterte sykdonmier som basofilisk leukemi, kronisk urtikaria og basofilisk leukocytose i mermesker og dyr; og inflammatoriske sykdonmier som karakteriseres ved T lymfocytter og profiise leukocytt infiltrater som psoriasis, eksem, inflanmiatorisk tarmsykdom, ulcerativ kolitt og Crohns sykdom, COPD (kronisk obstruktiv pulmonær forstyrrelse) og artritt.
NO20055588A 2003-04-25 2005-11-25 Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2 NO20055588L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03009384A EP1471057B1 (en) 2003-04-25 2003-04-25 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
PCT/EP2004/003910 WO2004096777A1 (en) 2003-04-25 2004-04-14 Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Publications (2)

Publication Number Publication Date
NO20055588D0 NO20055588D0 (no) 2005-11-25
NO20055588L true NO20055588L (no) 2006-01-24

Family

ID=32946880

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055588A NO20055588L (no) 2003-04-25 2005-11-25 Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2

Country Status (32)

Country Link
US (2) US7812160B2 (no)
EP (2) EP1471057B1 (no)
JP (2) JP4671955B2 (no)
KR (1) KR101110491B1 (no)
CN (2) CN101914065A (no)
AR (1) AR043885A1 (no)
AT (2) ATE316077T1 (no)
AU (1) AU2004233966B2 (no)
BR (1) BRPI0409733A (no)
CA (1) CA2523439C (no)
CL (1) CL43596B (no)
CY (1) CY1111295T1 (no)
DE (2) DE60303238T2 (no)
DK (2) DK1471057T3 (no)
DO (1) DOP2004000875A (no)
ES (2) ES2257616T3 (no)
GT (1) GT200400079A (no)
HN (1) HN2004000129A (no)
IL (1) IL171566A (no)
MX (1) MXPA05011399A (no)
MY (1) MY147984A (no)
NO (1) NO20055588L (no)
NZ (1) NZ543693A (no)
PE (1) PE20050143A1 (no)
PL (1) PL1633726T3 (no)
PT (2) PT1471057E (no)
RU (1) RU2361865C2 (no)
SI (1) SI1633726T1 (no)
TW (1) TWI353980B (no)
UY (1) UY28286A1 (no)
WO (1) WO2004096777A1 (no)
ZA (1) ZA200508722B (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
LT2805728T (lt) * 2003-12-23 2020-05-25 Genentech, Inc. Nauji anti-il 13 antikūnai ir jų naudojimai
BRPI0507123A (pt) 2004-01-31 2007-06-19 Actimis Pharmaceuticals Inc composto, medicamento, uso de um composto, e, processo para controlar um distúrbio ou doença associadas com a atividade de crth2 no ser humano e animais
BRPI0508540B8 (pt) 2004-03-11 2021-05-25 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
US8524715B2 (en) 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
KR101380448B1 (ko) 2005-04-21 2014-04-11 메르크 세로노 에스. 에이. ２，３치환된 피라진 술폰아미드
DK1891075T3 (da) 2005-05-24 2011-12-19 Merck Serono Sa Tricykliske spiroderivater som CRTH2-modulatorer
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
WO2007039736A1 (en) * 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
AU2007256597A1 (en) * 2006-06-09 2007-12-13 Icos Corporation Substituted phenyl acetic acids as DP-2 antagonists
CA2679198C (en) 2007-02-26 2011-07-12 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MY149005A (en) * 2007-06-21 2013-06-28 Actimis Pharmaceuticals Inc Amine salts of a crth2 antagonist
NZ581811A (en) * 2007-06-21 2012-11-30 Actimis Pharmaceuticals Inc Particulates of the CRTH2 antagonist { 4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)-benzyl)pyrimidin-5-yl} acetic acid
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
PT2205569E (pt) * 2007-09-25 2012-05-25 Actimis Pharmaceuticals Inc Alquiltiopirimidinas como antagonistas de crth2
AR068633A1 (es) * 2007-09-25 2009-11-25 Actimis Pharmaceuticals Inc Pirimidinas sustituidas con 2-s- bencilo como antagonistas de crth2
US8168678B2 (en) 2008-02-01 2012-05-01 Panmira Pharmaceuticals, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
TWI403319B (zh) 2008-07-03 2013-08-01 Panmira Pharmaceuticals Llc 前列腺素ｄ2受體之雜烷基拮抗劑
EP2328876B1 (en) * 2008-09-02 2012-11-21 Actimis Pharmaceuticals, Inc., Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
KR20110098749A (ko) * 2008-12-25 2011-09-01 다이쇼 세이야꾸 가부시끼가이샤 이소퀴놀린 유도체
EP2393492A1 (en) * 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CA2751260A1 (en) 2009-02-12 2010-08-19 Stefano Crosignani Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
JP2013500978A (ja) 2009-07-31 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２受容体アンタゴニストの眼の医薬組成物
MX2012001542A (es) 2009-08-05 2012-06-19 Panmira Pharmaceuticals Llc Antagonista dp2 y usos del mismo.
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
JP2013512242A (ja) * 2009-11-24 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリミジン−５−イル酢酸誘導体のコリン塩の多形体を調製する方法
KR20120115989A (ko) 2010-01-06 2012-10-19 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
SG182684A1 (en) 2010-01-27 2012-08-30 Boehringer Ingelheim Int Pyrazole compounds as crth2 antagonists
SG186737A1 (en) 2010-06-23 2013-02-28 Taisho Pharmaceutical Co Ltd Isoquinoline derivative
CA2805452C (en) 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
JP2013535457A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
EP2598143A1 (en) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
CN102803407B (zh) 2010-10-20 2016-11-16 威士伯采购公司 对包括铁素体不锈钢在内的宽范围的经涂布和未经涂布的基材具有改善粘附性的水基涂料体系
MX2013005478A (es) 2010-11-15 2013-08-29 Univ Leuven Kath Compuestos heterociclicos condensados antivirales.
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
TWI527809B (zh) 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物
EP2688882B1 (en) 2011-03-25 2015-05-13 Boehringer Ingelheim International GmbH Pyrazole compounds as crth2 antagonists
DK2709988T3 (en) * 2011-05-16 2017-09-18 Actimis Pharmaceuticals Inc METHOD FOR PREPARING [4,6-BIS-DIMETHYLAMINO-2- [4- (4-TRIFLUORMETHYLBENZOYL-AMINO) BENZYL] PYRIMIDIN-5-YL] ACETIC ACID
MX2014007239A (es) 2011-12-16 2014-08-08 Atopix Therapeutics Ltd Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica.
ES2624379T3 (es) 2011-12-21 2017-07-14 Idorsia Pharmaceuticals Ltd Derivados de heterociclilo y su uso como moduladores del receptor de prostaglandina D2
JP6127135B2 (ja) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
US20140148470A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9125842D0 (en) * 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
RU2181360C2 (ru) * 1996-09-06 2002-04-20 Ниппон Каяку Кабусики Кайся Новые производные ацетамида, способ их получения, фармацевтический состав и ингибиторы протеаз на их основе
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
CA2408727A1 (en) * 2000-05-22 2001-11-29 Leo Pharma A/S Benzophenones as inhibitors of il-1.beta. and tnf-.alpha.
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
EP1585511B1 (en) 2002-12-20 2013-01-23 Amgen Inc. Asthma and allergic inflammation modulators
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
NZ581811A (en) 2007-06-21 2012-11-30 Actimis Pharmaceuticals Inc Particulates of the CRTH2 antagonist { 4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)-benzyl)pyrimidin-5-yl} acetic acid
MY149005A (en) 2007-06-21 2013-06-28 Actimis Pharmaceuticals Inc Amine salts of a crth2 antagonist

Also Published As

Publication number Publication date
UY28286A1 (es) 2004-11-30
PT1633726E (pt) 2011-02-22
US20070129355A1 (en) 2007-06-07
AU2004233966A1 (en) 2004-11-11
KR20060089622A (ko) 2006-08-09
AR043885A1 (es) 2005-08-17
DE602004030907D1 (de) 2011-02-17
JP2006524645A (ja) 2006-11-02
CA2523439A1 (en) 2004-11-11
ATE316077T1 (de) 2006-02-15
US7812160B2 (en) 2010-10-12
DE60303238T2 (de) 2006-09-14
RU2361865C2 (ru) 2009-07-20
TWI353980B (en) 2011-12-11
CN1809539B (zh) 2012-05-09
DK1633726T3 (da) 2011-03-28
EP1633726B1 (en) 2011-01-05
BRPI0409733A (pt) 2006-05-09
SI1633726T1 (sl) 2011-04-29
TW200505873A (en) 2005-02-16
PT1471057E (pt) 2006-05-31
EP1633726A1 (en) 2006-03-15
JP2011068657A (ja) 2011-04-07
PE20050143A1 (es) 2005-04-01
AU2004233966B2 (en) 2010-11-11
CA2523439C (en) 2012-06-19
EP1471057A1 (en) 2004-10-27
HK1095320A1 (en) 2007-05-04
EP1471057B1 (en) 2006-01-18
CN1809539A (zh) 2006-07-26
US7960393B2 (en) 2011-06-14
CL43596B (es) 2005-03-18
NO20055588D0 (no) 2005-11-25
RU2005136655A (ru) 2006-06-10
MXPA05011399A (es) 2006-05-31
PL1633726T3 (pl) 2011-06-30
ES2257616T3 (es) 2006-08-01
GT200400079A (es) 2004-11-30
HN2004000129A (es) 2009-05-14
DOP2004000875A (es) 2004-10-31
JP5161290B2 (ja) 2013-03-13
ES2358424T3 (es) 2011-05-10
WO2004096777A1 (en) 2004-11-11
CY1111295T1 (el) 2015-08-05
ATE494279T1 (de) 2011-01-15
KR101110491B1 (ko) 2012-01-31
NZ543693A (en) 2009-05-31
CN101914065A (zh) 2010-12-15
ZA200508722B (en) 2006-12-27
IL171566A (en) 2011-03-31
MY147984A (en) 2013-02-28
DK1471057T3 (da) 2006-05-15
JP4671955B2 (ja) 2011-04-20
US20100322980A1 (en) 2010-12-23
DE60303238D1 (de) 2006-04-06

Similar Documents

Publication Publication Date Title
NO20055588L (no) Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2
CY1109274T1 (el) Παραγωγα ιμιδαζο[1,2-c] πυριμιδινυλοξικου οξεος
NO20054878L (no) 2-Fenoksy- og 2-fenylsulfonamidderivater med CCR3-antagonistisk aktivitet for behandling av astma og andre inflammasjons- eller immunologiske forstyrrelser
UA88485C2 (en) 2,6-substituted-4-monosubstituted amino-pyrimidines as prostaglandin d2 receptor antagonists
NO996490L (no) Substituerte benzanilider som CCR5-reseptorligander, anti- inflammatoriske midler og antivirale midler
UA95950C2 (en) 2,6-substituted-4-monosubstituted amino-pyrimidineasprostaglandin d2 receptor antagonists
TW200610757A (en) New pyridazin-3(2H)-one derivatives
NO20076450L (no) Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi
TNSN08515A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
SG155909A1 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
WO2004011427A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
AU2012316912A8 (en) Novel heterocyclic derivatives and their uses
WO2004010943A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
TW200639151A (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
ATE516277T1 (de) Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten
MX2009003100A (es) Inhibidores de fosfodiesterasa tipo iv.
JO2525B1 (en) Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
TW200635932A (en) New pyridothienopyrimidine derivatives
NO20065757L (no) Purinderivater
EP1666473A4 (en) CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENT
TW200631954A (en) New pyridothienopyrimidine derivatives
WO2007062318A3 (en) Chemical compounds
NO983831D0 (no) Nye substituerte N-metyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamider som er anvendbare for behandling av allergiske sykdommer
WO2005058898A3 (en) Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors
DE602006016244D1 (de) Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application